Month: April 2026

Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced  positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, in addition to the previously reported favorable safety profile. Key findings include: ·      Stable disease observed in >30% of evaluable patients ·      Prolonged treatment duration includes one patient extending beyond 16 months. ·      35% of patients remain on therapy...

Board appoints Cary Vance as President and Chief Executive OfficerFollows successful interim tenure and thorough search process by the BoardJan Stern Reed elected as Chair of the AVITA Medical BoardVALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) — AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member. “Following a thorough search process conducted in coordination with a top-tier, international executive search firm, the Board unanimously...

SINGAPORE, April 30, 2026 (GLOBE NEWSWIRE) — Primech Holdings Limited (Nasdaq: PMEC) (“Primech” or the “Company”), a Singapore-based provider of integrated facility services, today announced that its wholly owned subsidiaries, Maint-Kleen Pte Ltd and Primech A & P Pte Ltd, have been awarded two separate three-year cleaning service contracts within Singapore’s industrial sector. The combined estimated contract value is approximately US$3.45 million (approximately S$4.66 million), to be recognized over the contract terms. Contract DetailsMaint-Kleen Pte Ltd has secured a three-year contract valued at approximately US$1.4 million to deliver ongoing cleaning services across industrial property sites, supporting recurring, high-frequency service requirements. Primech A & P Pte Ltd has secured a three-year contract valued...

HAUPPAUGE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) — Orbit International Corp. (the “Company”) (OTCID Basic Market:ORBT), an electronics manufacturer and software solution provider, today announced that its subsidiary, Q-Vio Corp. (“Q-Vio”) has received additional prototype orders from its customer Technology Advancement Group (“TAG”). These prototype orders are in support of TAG’s continued testing of its handheld unit being developed by TAG that will be used to upgrade and replace the Defense Advanced GPS Receiver (“DAGR”) for the United States Department of War and select foreign military services. Q-Vio will provide an LCD assembly as well as other parts adding to the protection and durability of TAG’s handheld unit. In June 2023, TAG was selected as the prime contractor for the effort to replace the DAGR. TAG’s handheld unit...

Rollout Across Select Campaigns Reflects Early-Stage Expansion into Grocery Segment TORONTO, April 30, 2026 (GLOBE NEWSWIRE) — BrandPilot AI Inc. (CSE: BPAI) (OTCQB: BPAIF) (“BrandPilot” or the “Company”), a performance marketing technology company focused on improving efficiency in digital advertising, today announced that a national Canadian grocery retailer has selected BrandPilot’s technology for a rollout across select digital campaigns. The work will focus on improving the quality of campaign signals, increasing audience precision, and enabling more efficient allocation of marketing spend across automated advertising channels. By addressing inefficiencies at the data and execution level, BrandPilot’s platform is designed to support more consistent and reliable performance outcomes at scale. “Grocery retail operates on high...

Groupama Assurances Mutuelles announces the filing of its 2025 Universal Registration Document in the ESEF xHTML format (European Single Electronic Format) with the French stock exchange regulatory authority, the Autorité des Marchés Financiers (AMF) on 29 April 2026. The Universal Registration Document includes, among other items, Groupama Assurances Mutuelles’ Annual Financial Report as well as the corporate governance report as approved by the Board of Directors of the Company. The Universal Registration Document in French is available for consultation by the public free of charge in accordance with applicable regulation, and can be found as of today on Groupama’s website www.groupama.com, under the « Analysts / Financial-publications » section (in French and in English) as well as on the AMF’s website (in French and in the ESEF xHTML...

The partnership renewal agreement signed earlier extends a 5-year collaboration focused on the deployment of Versus Systems’ Filter Fan Cam technology, allowing fans to appear on stadium video boards with branded filters, overlays, and real-time visual effects. The system creates interactive fan engagement opportunities for teams and brands, with updated technology that includes a new C++ tracking engine, improved face detection, and reduced latency. The additional agreement expands the scope of Versus’ Filter Fan Cam deployment, increasing the volume and variety of Augmented Reality AR fan experiences available to Rangers’ audiences. The partnership and additional agreement highlight Versus’ strategy of monetizing audience participation across sports and entertainment venues.MIAMI, April 30, 2026 (GLOBE NEWSWIRE) — Versus Systems...

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1. “We are pleased to announce this milestone for the FORTIFY trial and the expansion into solid tumor cohorts that we believe are supported by PLN-101095’s mechanism of action,” said Bernard Coulie, M.D., Ph.D.., Chief Executive Officer of Pliant. “As a leader in integrin drug development, we look forward to exploring the full potential of this novel drug candidate.” FORTIFY...

Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S.  Strong physician interest at recent Society of Interventional Radiology conference and rising awareness across markets outside the U.S. supports commercial readiness throughout heavily populated regions HINGHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, is continuing to implement its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe, the Middle East and Asia (EMEA). The Company will continue to prioritize its commercial efforts in the U.S. market, while establishing regulatory, operational, and commercial...